Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Koji Haratani"'
Autor:
Hiroaki Kanemura, MD, MPH, Hidetoshi Hayashi, MD, PhD, Shuta Tomida, PhD, Junko Tanizaki, MD, PhD, Shinichiro Suzuki, MD, PhD, Yusuke Kawanaka, MD, Asuka Tsuya, MD, Yasushi Fukuda, MD, Hiroyasu Kaneda, MD, PhD, Keita Kudo, MD, Takayuki Takahama, MD, PhD, Ryosuke Imai, MD, Koji Haratani, MD, PhD, Yasutaka Chiba, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100373- (2022)
Introduction: Despite a considerable benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy for patients with extensive-stage SCLC (ES-SCLC), a durable response to ICIs occurs in only a small minority of such patients. M
Externí odkaz:
https://doaj.org/article/dbb20eead9094769a8713112200e34c2
Autor:
Koji Haratani, Hidetoshi Hayashi, Takayuki Takahama, Yasushi Nakamura, Shuta Tomida, Takeshi Yoshida, Yasutaka Chiba, Takahiro Sawada, Kazuko Sakai, Yoshihiko Fujita, Yosuke Togashi, Junko Tanizaki, Hisato Kawakami, Akihiko Ito, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, we investigated the potential of CUP for immunotherapy. Met
Externí odkaz:
https://doaj.org/article/4c66ac95b41d4d21b4969c357886ab3f
Publikováno v:
BMC Medicine, Vol 18, Iss 1, Pp 1-3 (2020)
Externí odkaz:
https://doaj.org/article/9cb4f75cf60f43a5856ee448a9aaecf0
Autor:
Kazuhiko Nakagawa, Seiichiro Mitani, Shinichiro Suzuki, Takashi Kurosaki, Yasumasa Nishimura, Hidetoshi Hayashi, Soichi Fumita, Naoki Otsuki, Kazuki Ishikawa, Takeshi Yoshida, Katsumi Doi, Hiroaki Kanemura, Koji Haratani, Kaoru Tanaka, Mutsukazu Kitano, Tsutomu Iwasa
Publikováno v:
Anti-Cancer Drugs
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic therapy has not been optimized. This study aimed to evaluate the safety a
Publikováno v:
BMC Medicine, Vol 18, Iss 1, Pp 1-3 (2020)
Autor:
Ryoji Kato, Naoyuki Maeda, Kaoru Tanaka, Masaaki Miyazawa, Kimio Yonesaka, Hidetoshi Hayashi, Kenji Hirotani, Hisato Kawakami, Masayuki Takeda, Koji Haratani, Kazuhiko Nakagawa, Kazuto Nishio, Junji Tsurutani, Naoki Takegawa, Takashi Kagari, Shiki Takamura, Katsumi Doi, Osamu Maenishi
Immunotherapy targeting programmed cell death-1 (PD-1) induces durable antitumor efficacy in many types of cancer. However, such clinical benefit is limited because of the insufficient reinvigoration of antitumor immunity with the drug alone; therefo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::add21f5a293464472f528b22f0a74f93
https://europepmc.org/articles/PMC6934205/
https://europepmc.org/articles/PMC6934205/
Autor:
Koji Haratani, Yasutaka Chiba, Shiki Takamura, Takafumi Okabe, Kenji Hirotani, Hiroyasu Kaneda, Michiko Yamato, Kaoru Tanaka, Shigeki Kato, Kazuhiko Nakagawa, Kazuto Nishio, Hidetoshi Hayashi, Yoshikazu Hasegawa, Masayuki Takeda, Kazuko Sakai, Kimio Yonesaka, Masaaki Miyazawa, Osamu Maenishi, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Hitomi Sakai, Keita Kudo
Publikováno v:
Clinical Cancer Research. 24:2653-2664
Purpose: Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non–small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby requiring alternative strategies. B7-H3, an immune-checkpoint molecule, is expressed
Autor:
Yasutaka Chiba, Hiroyasu Kaneda, Keita Kudo, Ryoji Kato, Kimio Yonesaka, Hidetoshi Hayashi, Kaoru Tanaka, Masayuki Takeda, Yoshikazu Hasegawa, Koji Haratani, Kazuhiko Nakagawa
Importance Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed cell death protein 1) inhibitors in patients with melanoma, but whether such an association exists for non–small-cell lung cancer (NSCLC) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c4e9d52f31831ed0e13ea080fabc50a
https://europepmc.org/articles/PMC6583041/
https://europepmc.org/articles/PMC6583041/